Related Experiment Video
Updated: Feb 18, 2026
11:09
Multiplex Detection of Bacteria in Complex Clinical and Environmental Samples using Oligonucleotide-coupled Fluorescent Microspheres
Published on: October 23, 2011
16.7K
Treatment for Symptomatic Bacterial Vaginosis: ARandomized Controlled Trial
Nabia Tariq1, Ayesha Basharat2, Danish Hassan Khan3
1Department of Obstetric Gynaecology, Shifa International Hospital, Islamabad.
Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
|November 15, 2017
Summary
Multiple doses of vaginal clindamycin effectively treat bacterial vaginosis, showing superior results compared to a single oral dose of secnidazole. This study highlights clindamycin
Area of Science:
- Gynecology
- Infectious Diseases
- Pharmacology
Background:
- Bacterial vaginosis (BV) is a common vaginal infection with significant health implications.
- Current treatment options for BV have varying efficacy and patient adherence.
- Novel therapeutic strategies are needed to improve BV management.
Purpose of the Study:
- To compare the effectiveness of multiple doses of vaginal clindamycin against a single oral dose of secnidazole for treating bacterial vaginosis.
- To evaluate the clinical cure rates for bacterial vaginosis using two different treatment regimens.
Main Methods:
- A double-blinded randomized controlled trial was conducted.
- Participants received either vaginal clindamycin or oral secnidazole.
- Treatment success was assessed by clinical and microbiological criteria on day 15.
Main Results:
- Vaginal clindamycin achieved a high cure rate of 96.6% for bacterial vaginosis.
- Oral secnidazole demonstrated a significantly lower cure rate of 23%.
Conclusions:
- Multiple doses of vaginal clindamycin are a more effective treatment for bacterial vaginosis than a single oral dose of secnidazole.
- Vaginal clindamycin offers a superior therapeutic option for managing bacterial vaginosis.
